Giovanni Maria Iannantuono

MedicineBiochemistry, Genetics and Molecular BiologyEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.”.

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4571

N/A

0.104DataRank · unranked

1 citations

Scot A. Niglio, Elias Chandran, Giovanni Maria Iannantuono, Salah Boudjadi, Rouf Banday +15 more

Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials

Cancer Treatment Reviews(2023)10.1016/j.ctrv.2023.102623

N/A

0DataRank · unranked

37 citations

Elias Chandran, Charalampos S. Floudas, Hyoyoung Choo‐Wosoba, Gisela Butera, Mario Roselli +3 more

Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study

medRxiv(2023)10.1101/2023.10.31.23297825

N/A

0DataRank · unranked

9 citations

Dara Bracken‐Clarke, Fatima Karzai, Hyoyoung Choo‐Wosoba, James L. Gulley, Charalampos S. Floudas +1 more

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4607

N/A

0DataRank · unranked

3 citations

Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Rouf Banday +15 more

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16506

N/A

0DataRank · unranked

0 citations

Elias Chandran, Nicholas I. Simon, Lisa Ley, Lisa M. Cordes, Tzu-fang Wang +13 more

Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study

The Oncologist(2024)10.1093/oncolo/oyae009

N/A

0DataRank · unranked

40 citations

Dara Bracken‐Clarke, Fatima Karzai, Hyoyoung Choo‐Wosoba, James L. Gulley, Charalampos S. Floudas +1 more

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis

BMJ Oncology(2024)10.1136/bmjonc-2024-000335

N/A

0DataRank · unranked

20 citations

Giovanni Maria Iannantuono, Saad Atiq, Dilara Akbulut, Ninet Sinaii, Nicholas I. Simon +11 more

Applications of large language models in cancer care: current evidence and future perspectives

Frontiers in Oncology(2023)10.3389/fonc.2023.1268915

N/A

0DataRank · unranked

114 citations

Dara Bracken‐Clarke, Charalampos S. Floudas, Mario Roselli, James L. Gulley, Fatima Karzai +1 more

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115589

N/A

0DataRank · unranked

6 citations

Charalampos S. Floudas, Marco Filetti, Tommaso Giovagnoli, Stefano Sganga, Antonio Vitale +13 more